Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

9.972 +0.252 (+2.59%)
Streaming Delayed Price Updated: 12:00 PM EDT, Jun 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immix Biopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Volume analysis on 2025-05-27: stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Friday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Discover the top movers in Friday's pre-market session. ↗
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 ↗
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 ↗
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
Immix Biopharma on Track to Dose NXC-201 Patients in United States
From Immix Biopharma, Inc.
Via GlobeNewswire
News headline image
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 ↗
IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
From Immix Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.